Arrowhead Research | ARWR - Operating Expenses


Arrowhead Research reported $223.22M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025